Cite
In re Brimonidine Patent Litigation: No infringement based on ANDA specifications and no invalidity based on an “obvious to try” analysis.
MLA
Rein, Frederick H., and Joseph B. Crystal. “In Re Brimonidine Patent Litigation: No Infringement Based on ANDA Specifications and No Invalidity Based on an ‘Obvious to Try’ Analysis.” Journal of Generic Medicines, vol. 8, no. 4, Oct. 2011, pp. 245–53. EBSCOhost, https://doi.org/10.1177/1741134311428103.
APA
Rein, F. H., & Crystal, J. B. (2011). In re Brimonidine Patent Litigation: No infringement based on ANDA specifications and no invalidity based on an “obvious to try” analysis. Journal of Generic Medicines, 8(4), 245–253. https://doi.org/10.1177/1741134311428103
Chicago
Rein, Frederick H, and Joseph B Crystal. 2011. “In Re Brimonidine Patent Litigation: No Infringement Based on ANDA Specifications and No Invalidity Based on an ‘Obvious to Try’ Analysis.” Journal of Generic Medicines 8 (4): 245–53. doi:10.1177/1741134311428103.